Recently, a number of American companies have witnessed an increasing trend towards offering their employees psychedelic drugs as a more effective alternative to traditional mental health treatments.

Recent studies have indicated the effectiveness of drugs previously known as recreational substances, such as MDMA (ecstasy) and Psilocybin (magic mushrooms), in addition to ketamine (approved for medical use), as alternative treatments for common psychological problems such as anxiety, depression, and post-traumatic stress disorder.

In a statement to the American newspaper "The Wall Street Journal", one of the American companies has already begun covering treatment using narcotic drugs for its employees in cooperation with the emerging company "Enthea" in the field of health insurance.

It is worth noting that the excessive focus on medications dispensed in the American health system drives the search for therapeutic alternatives, in the belief that new treatments will save treatment costs in the long term and will also contribute to improving employee happiness and productivity.